We are live on ! Find out more
VMI

VHCP Management III Portfolio holdings

AUM $504M
1-Year Est. Return 683.12%
This Fund
S&P 500
This Quarter Est. Return
+363.21%
1 Year Est. Return
+683.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$504M
AUM Growth
+$342M
Cap. Flow
+$112M
Cap. Flow %
22.32%
Top 10 Hldgs %
90.41%
Holding
26
New
9
Increased
2
Reduced
5
Closed
8

Top Buys

Rank Stock Value
1
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$70.7M
2
ETNB
89bio
ETNB
+$26.7M
3
RLMD icon
Relmada Therapeutics
RLMD
+$23.3M
4
ADVM
Adverum Biotechnologies
ADVM
+$8.34M
5
FTSV
Forty Seven, Inc. Common Stock
FTSV
+$8.29M

Top Sells

Rank Stock Value
1
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$15.9M
2
LJPC
La Jolla Pharmaceutical Company
LJPC
+$11M
3
PTGX icon
Protagonist Therapeutics
PTGX
+$9.85M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$7.76M
5
AXSM icon
Axsome Therapeutics
AXSM
+$2.56M

Sector Composition

Rank Sector Weight
1 Healthcare 97.82%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AXSM icon
1
Axsome Therapeutics
AXSM
$11.2B
$160M 31.77%
1,547,994
-63,335
-4% -$2.56M
CNST
2
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$119M 23.54%
2,516,242
+2,449,575
+3,674% +$70.7M
MIST icon
3
Milestone Pharmaceuticals
MIST
$138M
$33.1M 6.57%
2,066,529
– –
RLMD icon
4
Relmada Therapeutics
RLMD
$557M
$29.9M 5.95%
+767,938
New +$23.3M
ETNB
5
DELISTED
89bio
ETNB
$25.2M 5%
+958,765
New +$26.7M
TXG icon
6
10x Genomics
TXG
$6B
$22.9M 4.54%
300,000
– –
FTSV
7
DELISTED
Forty Seven, Inc. Common Stock
FTSV
$20.3M 4.04%
+516,381
New +$8.29M
ITCI
8
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$19.7M 3.92%
+575,000
New +$6.9M
ISEE
9
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$14.6M 2.9%
+1,699,797
New +$6.07M
KALV
10
DELISTED
KalVista Pharmaceuticals
KALV
$11M 2.19%
619,905
-17,979
-3% -$235K
ADVM
11
DELISTED
Adverum Biotechnologies
ADVM
$10.9M 2.16%
+94,623
New +$8.34M
MRNS
12
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$10.8M 2.15%
1,254,041
+625,000
+99% +$3.51M
MRSN
13
DELISTED
Mersana Therapeutics
MRSN
$8.95M 1.78%
+62,456
New +$4.57M
MYOV
14
DELISTED
Myovant Sciences Ltd.
MYOV
$7.07M 1.4%
+455,255
New +$4.59M
NXTC icon
15
NextCure
NXTC
$16.8M
$6.74M 1.34%
+9,974
New +$5M
OBSV
16
DELISTED
ObsEva SA Ordinary Shares
OBSV
$3.1M 0.61%
810,264
-349,525
-30% -$1.82M
PTGX icon
17
Protagonist Therapeutics
PTGX
$8.79B
$571K 0.11%
80,929
-991,419
-92% -$9.85M
BLPH
18
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
$134K 0.03%
25,597
-135,551
-84% -$862K
BCRX icon
19
BioCryst Pharmaceuticals
BCRX
$2.28B
– –
-2,708,207
Closed -$7.76M
KNSA icon
20
Kiniksa Pharmaceuticals
KNSA
$5.8B
– –
-277,137
Closed -$2.36M
KA
21
DELISTED
Kineta, Inc. Common Stock
KA
– –
-1,580
Closed -$187K
TCDA
22
DELISTED
Tricida, Inc. Common Stock
TCDA
– –
-80,348
Closed -$2.48M
RDUS
23
DELISTED
Radius Health, Inc.
RDUS
– –
-23,131
Closed -$596K
PRVL
24
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
– –
-4,408
Closed -$54K
RARX
25
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
– –
-670,350
Closed -$15.9M
1
2

Similar funds

BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
LB
Landmark Bank Columbia, Missouri $444M AUM 30.12% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
VOAM
Vertex One Asset Management Vancouver, British Columbia, Canada $434M AUM 37.82% 1-Year Est. Return
PC
Passport Capital San Francisco, California $394M AUM 50.67% 1-Year Est. Return
FFSOTS
Fiduciary Financial Services of The Southwest Dallas, Texas $382M AUM 25.98% 1-Year Est. Return
SC
Southside Capital Miami Beach, Florida $382M AUM 30.29% 1-Year Est. Return

VHCP Management III's Q4 2019 Portfolio in Review

As of Q4 2019, VHCP Management III held 26 positions worth $504M, up 211% from $162M the previous quarter. Its ten largest holdings account for 90% of the portfolio.

VHCP Management III deployed $112M of net new capital in Q4 2019, opening 9 new positions and adding to 2 existing holdings. Its largest new stake was 89bio: 958,765 shares worth $25.2M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier.

On the sell side, the largest reduction was Protagonist Therapeutics, an estimated $9.85M trimmed.

  • VHCP Management III's largest Q4 2019 buy was 89bio: 958,765 shares worth $25.2M.
  • VHCP Management III added most to Constellation Pharmaceuticals, Inc. in Q4 2019, an estimated $70.7M increase.
  • VHCP Management III's biggest Q4 2019 reduction was Protagonist Therapeutics, cutting an estimated $9.85M.
  • VHCP Management III fully exited Ra Pharmaceuticals, Inc. Common Stock in Q4 2019, selling an estimated $15.9M.
  • VHCP Management III's ten largest holdings make up 90% of its $504M portfolio in Q4 2019.
  • VHCP Management III opened 9 new positions and closed 8 in Q4 2019.
  • VHCP Management III's portfolio value rose 211% quarter-over-quarter to $504M.

Based on VHCP Management III's 13F filing for Q4 2019, filed 13 Feb 2020.